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radiotherapy, with the aim to verify possible correlations 
between the planned dose distributions to the main dose 
limiting structures and the observed levels of toxicity like 
mucositis, xerostomia and dysphagia. 
 
Material and Methods: Data of hystologically confirmed 
advanced HNC patients, in stage III and IV (AJCC), were 
reviewed in a retrospective dosimetric and clinical 
evaluation. Patients were treated with VMAT (RapidArc) and 
SIB in 33 fractions for a total dose of 69.96 Gy to the tumor 
and positive-nodes, and 54.45Gy to the elective volume, 
respectively. Toxicity was graded according to CTCAE3.0 
Correlation was explored between OAR dose parameters and 
related acute and late toxicities. 
 
Results: From December 2008 to August 2014, 102 patients 
were treated. Acute mucosal and swallowing toxicities higher 
than grade 3 were reported in only 11% and 6% of patients, 
respectively; late morbidities (G1-G2) were present in only 
3% of cases. No G3 Toxicity was reported. A statistically 
significant correlation was found between the dosimetric 
parameters of oral cavity V30Gy, V40Gy, and V70Gy, and 
mucosal toxicity (p = 0.01, 0.03, and 0.05, respectively). 
Concerning salivary glands, late toxicity profile was worse 
compared to acute side effects, with 19% of persisting late 
grade equal or higher than 2. Regarding the constrictors and 
the swallowing toxicity, most of the dosimetric parameters of 
the inferior constrictor muscle (mean dose, D1/2V, D1/3V, 
D2/3V) were significant at the univariate analysis, while no 
correlations were found for middle and superior constrictors. 
With a median follow-up of 19 months (range 1-61 months), 
Overall Survival (OS) at 3 and 5 years was 83%±4% and 
73%±10%. Mean OS was 51±3 months. Disease Free Survival 
(DFS) at 3 and 5 years was 71%±7%, and 34%±16%. Mean DFS 
was 43±3 months. 
 
Conclusion: Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB), that allow a shorter 
overall treatment time, a dose escalation, associated with a 
better sparing of OARs, showed a good toxicity profile. From 
our analysis toxicity to dose-limiting structures was 
significantly correlated to the dosimetric parameters 
explored. 
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Purpose or Objective: To investigate the association 
between temporally robust domains of patient-reported 
trismus symptoms with mouth-opening ability as assessed by 
maximal interincisal opening distance (MIO) in head and neck 
cancer (HNC) patients treated with radiotherapy (RT). 
 
Material and Methods: The study included 196 patients 
previously treated with primary state-of-the-art RT for HNC 
in 2007-2012. A five answering-category-based 
(no/mild/moderate/severe/very severe symptom) patient-
reported trismus questionnaire (Gothenburg Trismus 
Questionnaire, GTQ) was completed pre-RT, and at 3, 6, and 
12 months post-RT. This study focuses on the 14/21 
potentially RT-induced physical trismus symptoms from GTQ. 
At each follow-up, symptom domains were generated by 
means of factor analysis and these symptoms were correlated 
with MIO (categorized into five intervals (mm): 1: >50; 2: 
>40-≤50; 3: >35-≤40; 4: >25-≤35; 5: ≤25) for each follow-up 
using Pearson’s correlation coefficient (Pr). 
 
Results: The three symptom domains Jaw aches/pains, Jaw-
related problems, and Eating limitations were identified at 
each follow-up, and included one, two and three temporally 
robust symptoms, respectively. Correlations between MIO and 
these symptoms were weak to modest (Pr= 0.22-0.58; Table) 
with the overall stronger correlations for ‘Opening mouth 
difficulty’ and ‘Current mouth-opening ability’ in the Jaw-
related problems domain at 6 and at 12 months post-RT 
(Pr=0.49-0.58; Figure). 
 
 
 
 
 
Conclusion: Mouth-opening distances can be explained in 
terms of associated patient-reported symptom severities on 
jaw-related problems. Translating the patient’s experience 
into objective measurements and vice versa widens 
possibilities to monitor and possibly prevent progression of 
trismus symptoms after RT. 
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Purpose or Objective: Determination of expression of EGFR 
in premalignant and malignant lesions of the oral cavity and 
evaluating the role of Gefitinib in the same 
 
Material and Methods: 130 Patients with premalignant and 
malignant lesions of oral cavity from JK cancer institute, 
Kanpur were selected. EGFR status evaluation was done in all 
the patients. Premalignant lesions over expressing EGFR were 
observed for transformation into malignant lesions and were 
given Tab Gefitinib 250 mg OD daily. Malignant lesions with 
over expression of EGFR were randomly divided into 2 groups 
first group consisted of patients who were given 
CCRT(cisplatin). The other group had the same regimen but 
with the addition of Tab Gefitinib 250 mg daily 
 
Results: Out of 130 patients registered 53 were premalignant 
out of which EGFR(+) positive in 73%( 39) patients. EGFR( 
++)over expression were in 8%(4)patients, EGFR negative in 
18%(10) patients. 77 were malignant lesions EGFR positive in 
89%(51) patients. EGFR(+)in 38%(27) of patients, EGFR(++)in 
40%( 28) patients ,EGFR(+++) were expressed by 11%( 11) 
patients. EGFR negative in 11%(11 patients) 
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Total of 40 Malignant Lesions were Randomized into the two 
arms 19patients(total 22) in CCRT+ gefitinib arm have shown 
complete response in comparison to 11patients(total 18) in 
CCRT arm  
 
Conclusion: EGFR status evaluation in premalignant can be 
used as a screening tool for detection of transformation into 
malignant lesions. We can prevent this transformation by 
EGFR inhibitors. In malignant lesions it can be really 
important for the role of EGFR inhibitors .Eg Gefitinib has 
shown good results when combined with the conventional 
CCRT. 
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Purpose or Objective: Increasingly limited health care 
resources coupled with a rising incidence of oropharyngeal 
squamous cell carcinoma (OPSCC) is resulting in longer wait 
times for definitive treatment. Our objectives were to 
determine the impact of treatment delays on disease 
upstaging and outcomes in OPSCC. 
 
Material and Methods: Demographic features, number of 
days from diagnosis until surgery, and clinical and 
pathological staging information were determined for 139 
patients diagnosed with OPSCC between January 2006 and 
November 2011. Patients were stratified on the basis of 
whether or not their disease was upstaged between clinical 
and pathological T, N or M stage. Statistics were performed 
using MedCalc Statistical Software. 
 
Results: A total of 62 (45%) of patients were upstaged. 
Upstaged patients had a longer median time to surgery 
compared to non-upstaged patients (81 vs 68 days, p=0.017) 
and 21% (n=13) were upstaged to T ≥ T3 or N ≥ N1. There was 
a trend to higher incidence of margin positivity in upstaged 
patients (19%, n=12) compared to non-upstaged patients (9%, 
n=7) (p=0.141). Groups did not differ in the rate of nodal 
extracapsular extension (50% and 41%, p=0.363). Median 
overall survival (OS) for upstaged patients was 5.82 years and 
was not reached for non-upstaged patients. There was a 
trend to lower OS in upstaged patients (p=0.0746).  
 
Conclusion: Longer duration between diagnosis and surgery is 
associated with significant pathological upstaging. Allocating 
resources to reduce treatment delays may result in overall 
health care savings due to a reduced rate of requirement for 
adjuvant treatment, reduced patient morbidity, and 
improvement in disease outcomes.  
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Purpose or Objective: The aim of this study was to 
investigate the impact assessment of Sankol drug on the 
excretion of 131I from patients with differentiated thyroid 
cancer (DTC). 
 
Material and Methods: Fifty-four patients with DTC who had 
normal renal function in two groups of control and 
intervention were included in this study. The herbal diuretic 
was given orally to the intervention group from 3 hours after 
the 131I administration, and then every 8 hours for 24 hours. 
The control patients received placebo with the same timing. 
The radioactivity of the urine samples from each maturation 
was measured and expressed as the percentage of the 
administered dose. Exposure from patients were measured 
after the drug administration and then at the time of 3, 9, 
15, 21 and 24 hours after the patient isolation. 
 
Results: The obtained mean percentage of activity excreted 
during 24 hours after intake of radioactive iodine in the urine 
in the intervention and control group were 68.85±4.3, 
59.11±5.3 with p<0.001 respectively. The obtained 
percentage of residual activity in the body after 24 hours was 
25.17±4.6, 19.56±3.6 with p < 0.001, respectively. Radiation 
dose rate at 300cm after 24 hours for the intervention and 
control group were 9.52±3.4 µSV/h, 11.92 ± 6.0µSV/h with p 
> 0.05, respectively. 
 
Conclusion: : Our results demonstrated that Sankol given as 
an adjuvant medication in the patients with DTC was caused 
a significant increase in urinary excretion of radioiodine and 
shorten the hospital stay. 
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Purpose or Objective: To present protocol larynx 
preservation results in patients treated for carcinoma of the 
larynx or hypopharynx in stage III and IV. 
 
Material and Methods: Data from a serie of 50 patients 
treated under the guidance of larynx preservation protocol 
implemented at our institution in 2007 were analyzed. 
Treatment protocol is divided into two phases. Patients 
meeting the inclusion criteria receive CDDP and 5FU cycle. At 
3 weeks CT evaluation is performed. If the answer is > 50% 
are included in the arm radiochemotherapy : CDDP every 3 
weeks and RT 70Gy 2 Gy per session 5 days a week. Those 
who do not respond or <50% are scheduled to total 
laryngectomy + neck dissection. If indicated received 
postoperative RT. The cases analyzed belong the period 
2007-2012 (minimum three years follow-up). All patients 
were considered evaluable.  
 
Results: The serie includes 50 patients with a median age of 
56 years. 42 men and 8 women with tumors in the larynx (28) 
and hypopharynx (22); 27 stage III and 23 stage IV. 22 not 
reached a sufficient response (<50%) and yes they got 27; in 
one case we missed the information. Laryngectomy was 
performed in 19 patients out of 22 unanswered (3 refused). 
Among the 27 respondents, received RT / CT, 6 LT for 
recurrences were performed. Larynx preservation was 
achieved in 50% of patients. The survival of the entire group 
was 51% at 5 years and 62.6% cause-specific survival. The 
specific survival at 5 years with RT / CT was 60% compared to 
65% of total laryngectomy gupo (p = 0.568).  
 
 
 
